Torkinib (PP242) is a selective inhibitor of mTOR (mammalian target of rapamycin), specifically targeting both mTORC1 and mTORC2 complexes. It is primarily used in research settings to study signaling pathways involved in cell growth, proliferation, and survival. Due to its ability to block protein synthesis and induce cell cycle arrest, it has been investigated for its potential in cancer therapy, particularly in tumors driven by hyperactive PI3K/Akt/mTOR signaling. Studies show it can suppress the growth of various cancer cell lines, including leukemia, breast, and prostate cancers. It is also used to explore autophagy modulation and metabolic regulation in cellular models. Its selectivity makes it a valuable tool compound in preclinical studies aiming to dissect mTOR-dependent biological processes.